BioVie Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

BioVie şirketinin toplam hissedar öz sermayesi $14.1M ve toplam borcu $3.3M olup, bu da borç-öz sermaye oranını 23.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $21.2M ve $7.2M dir.

Anahtar bilgiler

23.6%

Borç/özkaynak oranı

US$3.32m

Borç

Faiz karşılama oranı	n/a
Nakit	US$20.02m
Eşitlik	US$14.07m
Toplam yükümlülükler	US$7.17m
Toplam varlıklar	US$21.24m

Son finansal sağlık güncellemeleri

Recent updates

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

Oct 14

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

Sep 06

BioVie: Four Potential Catalysts Around The Corner

Jun 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIVI 'nin kısa vadeli varlıkları ( $20.2M ) kısa vadeli yükümlülüklerini ( $6.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: BIVI şirketinin kısa vadeli varlıkları ( $20.2M ) uzun vadeli yükümlülüklerini ( $332.7K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIVI şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: BIVI şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BIVI şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: BIVI serbest nakit akışı tahminlerine göre 11 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

BioVie Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Inc. Contemplates Bankruptcy

BioVie Inc. Contemplates Bankruptcy

Recent updates

Biovie Inc. to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long Covid At Theemystifying Long Covid International Conference

BioVie Inc.'s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has filed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.00075 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.6645 million.

BioVie Inc. has filed a Follow-on Equity Offering in the amount of $6.6645 million.

BioVie Inc. Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $2.995764 million.

New major risk - Market cap size

BioVie Inc. has filed a Follow-on Equity Offering.

BioVie Inc., Annual General Meeting, Nov 07, 2024

BioVie Inc. Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long Covid

Biovie Inc. Announces Fda Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long Covid

Biovie Inc. Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process At the 11Th Aging Research and Drug Discovery Meeting

BioVie Inc. Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’S Disease

New minor risk - Share price stability

BioVie Inc. Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024

BioVie Inc. Announces Its Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

New major risk - Financial position

BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $21 million.

New major risk - Shareholder dilution

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Independent Director recently sold US$128k worth of stock

New minor risk - Market cap size

BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

New major risk - Share price stability

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023

BioVie Inc., Annual General Meeting, Nov 08, 2023

Price target increased by 11% to US$11.50

Insufficient new directors

BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson’s Disease and Movement Disorders

Biovie Inc. Announces Phase 3 Trial of Ne3107 in Alzheimer's Disease

BioVie Inc. to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

Biovie Inc. Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: Ne3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

BioVie Inc. Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

Biovie Inc. Phase 3 Trial Assessing Ne3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients

BioVie Inc. Phase 2 Trial Assessing Ne3107's Pro-Motoric Activity in Parkinson's Disease Is Fully Enrolled

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

BioVie Inc., Annual General Meeting, Nov 09, 2022

BioVie Inc. Announces Topline Results from an Investigator-Sponsored Phase 2 Clinical Trial of NE3107 for the Treatment of Alzheimer’s Disease

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

BioVie Inc. announced that it has received $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

BioVie: Four Potential Catalysts Around The Corner

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

BioVie Inc. Contemplates Bankruptcy

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Biovie Announces First Patient Enrolled in Phase 3 Study of Ne3107 in Alzheimer’s Disease

BioVie Inc. Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

BioVie Inc. Contemplates Bankruptcy

BioVie Commences Patient Screening in Phase 2 Clinical Trial

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $15.652 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin